The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

MPN Advances Day 2019 | Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways

Name: Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways
Uploaded: 2019-11-15T00:00:00.000Z
Duration: 2 min 23 s
Description: Speaking at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the latest treatments in development for myelofibrosis, as well as understanding of the disease. He highlights JAK inhibitors, as well as other pathway inhibitors such as LSD1, BET, MDM2 and TGF-β.

Ruben Mesa • 15 Nov 2019

MPN Advances Day 2019

Myeloproliferative Neoplasms Fedratinib Momelotinib Pacritinib

Speaking at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the latest treatments in development for myelofibrosis, as well as understanding of the disease. He highlights JAK inhibitors, as well as other pathway inhibitors such as LSD1, BET, MDM2 and TGF-β.